A nanoprobe system for in vivo use comprises a plasmonic-active nanoparticle and a molecular probe system. The molecular probe system comprises an oligonucleotide capable of forming a stem-loop configuration, having a first end and a second end, wherein the oligonucleotide is immobilized to the plasmonic-active nanoparticle at the first end and labeled with a Raman reporter at the second end, a placeholder strand at least partially bound to the oligonucleotide, and an attachment mechanism for attachment to a cell membrane.

Methods, systems and computer-accessible medium for imaging a living cell or a living organism with bond-edited compounds using stimulated Raman scattering are disclosed. The method comprises the steps of introducing one or more bond-edited compounds into a live cell or a living organism, and detecting a vibrational tag in the cell or organism with stimulated Raman scattering. Also disclosed are methods for detecting a disease condition in a subject, methods for monitoring treatment for a disease condition, methods for screening an agent, methods for tracing a cellular process in a live cell using bond-edited compounds in combination with stimulated Raman scattering. Also disclosed are a composition for labeling a target cell with at least one bond-edited compound and devices for imaging bond-edited compounds by stimulated Raman scattering.

Antibodies which bind selectively to cardiac conduction system (CCS) cells, imaging and/or diagnostic reagents and compositions visualizing the CCS cells and therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention. Compositions and methods for isolation, purification, analyses and/or transplantation of the CCS cells, including pluripotent stem cell (hiPSC)-derived or human embryonic stem cell (hESC)-derived CCS cells.

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

A dye loaded zeolite composite material comprises a plurality of zeolite crystals each having a plurality of straight through uniform channels extending between the proximal face and the distal face and having a channel axis parallel to and a channel width transverse to a longitudinal crystal axis A. Each channel contains a substantially linear arrangement of dye molecules comprising first and second dye molecules having an elongated shape with a longitudinal extension exceeding said channel width and a lateral extension not exceeding said channel width. Each dye molecule consists of a chromophore moiety arranged between a pair of terminal moieties, wherein: the chromophore moieties of the first and second dye molecules are substantially identical, the terminal moieties of the first dye molecules have a lateral extension larger than half of the channel width, the terminal moieties of the second dye molecules have a lateral extension smaller than half of the channel width, the linear arrangement of dye molecules comprises at least one pair of second dye molecules adjacent each other.

A polynucleotide encoding a biosensor polypeptide comprising a modified circularly-permuted thermostable luciferase and a linker linking the C-terminal portion of the thermostable luciferase to the N-terminal portion of the thermostable luciferase. The modified circularly-permuted thermostable luciferase is modified relative to a parental circularly-permuted thermostable luciferase. The linker contains a sensor region capable of interacting with a target molecule in a cell. The modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the parental circularly-permuted thermostable luciferase in the presence of the target molecule. Alternatively, the modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the modified circularly-permuted thermostable luciferase in the absence of the target molecule.

A bioluminescence energy transfer (BRET) nanosystem having semiconductive quantum rods (QRs) bound by firefly luciferase Photinus pyralis (Ppy) for improved conversion of chemical energy to light, such as in solid-state lighting, near-infrared imaging systems, and in vivo infrared imaging. The nanosystems are formed by synthesizing CdSe/CdS or CdSe/CdS/ZnS quantum rods, rendering the dots hydrophilic and colloidially stable with a facile His-capping, incubating with a Ppy variant (PpyGRTS) at increasing loading ratios, and adding an excess of the luciferin (LH2) substrate to the PpyGRTS-QRs.

The purpose of the present invention is to provide a cyclic peptide having any unit structure selected from the structures represented by the following formula (1):

—X.sup.1—X.sup.2—X.sup.3—X.sup.4—X.sup.5—  (1) (in the formula (1), X.sup.1 is I, V or L, or an N-alkylamino acid thereof, X.sup.2 is S or T, or an N-alkylamino acid thereof, X.sup.3 is K or an N-alkylamino acid thereof, X.sup.4 is W or an N-alkylamino acid thereof, and X.sup.5 is W, Y, or H, or K or an N-alkylamino acid thereof), or a pharmaceutically acceptable salt of the cyclic peptide.

The present disclosure discloses methods and compositions for administering Cerenkov radiation-induced therapy (CRIT).